Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Series A Preferred Stock	Class A Common Stock	Class B Common Stock	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
Balance at Dec. 31, 2020				$ 142,346,852	$ (87,300,472)	$ (48,539)	$ 11,949,200	$ 66,947,041
Balance (in Shares) at Dec. 31, 2020	28,055	35,497	55,008
Effect of reverse acquisition
Effect of reverse acquisition (in Shares)	18,099,548	22,900,719	35,488,938
Conversion of share due to merger recapitalization		$ 7,649						7,649
Conversion of share due to merger recapitalization (in Shares)	(18,099,548)	(22,900,719)	(35,488,938)
Effect of reverse acquisition		$ 7,649		142,346,852	(87,300,472)	(48,539)	11,949,200	66,954,690
Effect of reverse acquisition (in Shares)		76,489,205
Share issued for services		$ 17						17
Share issued for services (in Shares)		171,608
Exercise of cashless warrants		$ 182						182
Exercise of cashless warrants (in Shares)		1,817,507
Issuance of shares net redemption and issuance costs of $9,566,304		$ 530		43,404,558				43,405,088
Issuance of shares net redemption and issuance costs of $9,566,304 (in Shares)		5,297,097
PIPE, net of issuance costs of $10,396,554		$ 1,250		114,602,318				114,603,568
PIPE, net of issuance costs of $10,396,554 (in Shares)		12,500,000
Exercise of stock options		$ 123		628,469				628,592
Exercise of stock options (in Shares)		1,235,131
Stock based compensation				1,376,353				1,376,353
Fair value of Warrants from reverse acquisition				(18,717,998)				(18,717,998)
U.K. Ltd. Shares purchase (Note 4)		$ 5		(479,336)			(242,945)	(722,276)
U.K. Ltd. Shares purchase (Note 4) (in Shares)		50,192
Sponsor Earnout shares		$ 257						257
Sponsor Earnout shares (in Shares)		2,573,213
Noncontrolling interest contribution							333,025	$ 333,025
Cashless exercise of options (in Shares)								1,235,130
Foreign currency translation						16,038		$ 16,038
Net loss attributable to Noncontrolling interests							(4,564,270)	(4,564,270)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries					23,743,758			23,743,758
Balance at Dec. 31, 2021		$ 10,013		283,161,216	(63,556,714)	(32,501)	7,475,010	227,057,024
Balance (in Shares) at Dec. 31, 2021		100,133,953
Equity cost				(19,570)				(19,570)
Exercise of stock options		$ 105		1,980,674				1,980,779
Exercise of stock options (in Shares)		1,053,401
Stock based compensation				7,183,992				7,183,992
Noncontrolling interest contribution							2,063,000	2,063,000
Common stock repurchased		$ (54)		(3,731,658)				(3,731,712)
Common stock repurchased (in Shares)		(536,839)
Cashless exercise of options		$ 36		(230)				$ (194)
Cashless exercise of options (in Shares)		354,276						1,699,720
Restricted stock units				495,579				$ 495,579
Share warrants conversion		$ 141		12,381,432				12,381,573
Share warrants conversion (in Shares)		1,406,371
Foreign currency translation						773,707		773,707
Net loss attributable to Noncontrolling interests							(3,841,285)	(3,841,285)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries					34,584,498			34,584,498
Balance at Dec. 31, 2022		$ 10,241		$ 301,451,435	$ (28,972,216)	$ 741,206	$ 5,696,725	$ 278,927,391
Balance (in Shares) at Dec. 31, 2022		102,411,162